SNS-595 and methods of using the same
The present invention relates to SNS-595 and methods of treating cancer using the same.
1. A method for treating cancer comprising administering to a human patient having cancer (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in a dose of about 10 mg/m 2 −100 mg/m 2 and a therapeutically effective amount of an anti-metabolite.
2. The method of claim 1 , wherein the dose of (+)-1,4-dihydro-7-[(3 S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to be administered is about 30 mg/m 2 -75 mg/m 2 .
3. The method of claim 1 , wherein the dose of (+)-1,4-dihydro-7-[(3 S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to be administered is about 40 mg/m 2 -80 mg/m 2 .
4. The method of claim 1 , wherein the dose of (+)-1,4-dihydro-7-[(3 S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to be administered is about 50 mg/m 2 -90 mg/m 2 .
5. The method of claim 1 , wherein the anti-metabolite is a folate analog, a purine analog, an adenosine analog, a pyrimidine analog or a substituted urea.
6. The method of claim 1 , wherein the cancer is lymphoma.
7. The method of claim 1 , wherein the anti-metabolite is fluorouracil.